

## References

I-180

1. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier CCTL019B2202, Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA); 2017.
2. Maude, Frey N, Shaw P, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. *N Engl J Med*. 2014;371:1507-1517.
3. Micromedex DrugDex Compendium®. 2024.Tisagenlecleucel.
4. Clinical Pharmacology™ Compendium. 2024..Tampa FL: Gold Standard, Inc. Tisagenlecleucel.
5. National Comprehensive Cancer Network (NCCN). Tisagenlecleucel. NCCN Drugs and Biologics Compendium®. 2023.
6. Kymriah™ (tisagenlecleucel) suspension for intravenous infusion [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. Revised 04/2024.
7. Grupp S, Buechner J, Bittencourt H. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/ refractory acute lymphoblastic leukemia [Abs 221]. *Blood*. 2016.
8. Buechner J, Grupp S, Maude S, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Update to the interim analysis [Abs S476]. *Haemato*. 2017.
9. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med*. 2017;1-12.
10. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378:439-48.
11. Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017; 1800-1808.
12. Neelapu S, Locke F, Bartlett N, et al. SCHOLAR-1 versus ZUMA-1: A standardized comparison of outcomes in patients (Pts) with refractory, aggressive Non-Hodgkin lymphoma (rNHL). *Clin Lymphoma Myeloma & Leuk*. 2017;S362-S363.
13. Neelapu S, Locke F, Bartlett N, et al. Axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphomas (nhl): primary results of the pivotal trial ZUMA-1. *Hematol Onco*. 2017;28.
14. Yescarta™ (axicabtagene ciloleucel) suspension for intravenous infusion [package insert]. Santa Monica, CA: Kite Pharma, Inc.Revised 04/2024.
15. Clinical Pharmacology™ Compendium. 2024.Tampa FL: Gold Standard, Inc. Axicabtagene Ciloleucel.
16. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2020;382:1331-1342.

17. Tecartus™ (brexucabtagene autoleucel) suspension for intravenous infusion [package insert]. Kite Pharma, Inc. Santa Monica, CA. Revised 10/2021.
18. Tecelra® (afamitresgene autoleucel) suspension for intravenous infusion [package insert]. Adaptimmune, LLC. Philadelphia, PA. Revised 08/2024.
19. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. brexucabtagene autoleucel.
20. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Afamitresgene autoleucel.
21. Micromedex DrugDex Compendium®. 2024. brexucabtagene autoleucel.
22. Micromedex DrugDex Compendium®. 2024. Idacabtagene Vicleucel.
23. Micromedex DrugDex Compendium®. 2024. Lisocabtagene Maraleucel.
24. Abecma® (idecabtagene vicleucel) suspension for intravenous infusion [package insert]. Celgene Corporation, a Bristol-Myers Squibb Co. Summit, NJ. 04/2024.
25. Breyanzi® (lisocabtagene maraleucel) suspension for intravenous infusion [package insert]. Juno Therapeutics, Inc. a Bristol-Myers Squibb Co. Bothell, WA. Revised 05/2024.
26. National Comprehensive Cancer Network (NCCN). Brexucabtagene autoleucel. NCCN Drugs and Biologics Compendium®. 2024.
27. National Comprehensive Cancer Network (NCCN). Idecabtagene. NCCN Drugs and Biologics Compendium®. 2024.
28. National Comprehensive Cancer Network (NCCN). Lisocabtagene maraleucel. NCCN Drugs and Biologics Compendium®. 2024.
29. National Comprehensive Cancer Network (NCCN). Axicabtagene ciloleucel). NCCN Drugs and Biologics Compendium®. 2024.
30. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Lisocabtagene maraleucel.
31. Micromedex DrugDex Compendium®. 2024. Axicabtagene Ciloleucel.
32. Carvykti™ (ciltacabtagene autoleucel) suspension for intravenous infusion [package insert]. Janssen Biotech, Inc., Horsham, PA. Revised 04/2024.
33. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. ciltacabtagene autoleucel.
34. Micromedex DrugDex Compendium®. 2024. Ciltacabtagene Autoleucel.
35. National Comprehensive Cancer Network (NCCN). Ciltacabtagene Autoleucel. NCCN Drugs and Biologics Compendium®. 2024.
36. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640-654.

37. Ogasawara K, Dodds M, Mack et al. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. *Clin Pharmacokinet.* 2021;60(12):1621-1633.
38. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. *Lancet.* 2023;402(10402):641-654.